Absci Future Growth

Future criteria checks 2/6

Absci is forecast to grow earnings and revenue by 21.2% and 42.9% per annum respectively while EPS is expected to grow by 27.8% per annum.

Key information

21.2%

Earnings growth rate

27.8%

EPS growth rate

Biotechs earnings growth	23.2%
Revenue growth rate	42.9%
Future return on equity	n/a
Analyst coverage	Good
Last updated	25 Mar 2024

Recent future growth updates

Recent updates

Merck And Absci: AI-Driven Drug Development Deal Has Promise, But May Take Years To Pay Out

Jan 10

IPO Day With Absci CEO Sean McClain - The Google Of Synthetic Biology (Video)

Jul 22

Earnings and Revenue Growth Forecasts

NasdaqGS:ABSI - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	43	-78	N/A	-47	4
12/31/2025	21	-87	-82	-48	6
12/31/2024	9	-93	-102	-61	6
12/31/2023	6	-111	-65	-65	N/A
9/30/2023	7	-106	-70	-68	N/A
6/30/2023	9	-112	-83	-77	N/A
3/31/2023	6	-99	-90	-80	N/A
12/31/2022	6	-105	-98	-81	N/A
9/30/2022	6	-111	-104	-80	N/A
6/30/2022	5	-107	-107	-83	N/A
3/31/2022	5	-121	-113	-74	N/A
12/31/2021	5	-103	-99	-61	N/A
9/30/2021	6	-84	-77	-46	N/A
6/30/2021	5	-73	-53	-27	N/A
3/31/2021	5	-48	-24	-16	N/A
12/31/2020	5	-49	-13	-11	N/A
12/31/2019	2	-24	-7	-6	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: ABSI is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: ABSI is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: ABSI is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: ABSI's revenue (42.9% per year) is forecast to grow faster than the US market (8.2% per year).

High Growth Revenue: ABSI's revenue (42.9% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if ABSI's Return on Equity is forecast to be high in 3 years time

Absci Future Growth

Future criteria checks 2/6

Key information

Recent future growth updates

Consensus revenue estimates fall by 20%

Consensus revenue estimates decrease by 13%

Price target decreased by 14% to US$5.76

Consensus revenue estimates decrease by 42%

Price target decreased by 15% to US$5.50

Consensus EPS estimates fall by 21%, revenue upgraded

Recent updates

Absci Corporation to Report Q1, 2024 Results on May 14, 2024

Consensus revenue estimates fall by 20%

Full year 2023 earnings: EPS in line with expectations, revenues disappoint

Consensus revenue estimates decrease by 13%

New minor risk - Shareholder dilution

Absci Corporation has filed a Follow-on Equity Offering in the amount of $75 million.

Absci Corporation has filed a Follow-on Equity Offering in the amount of $75 million.

Absci: Differentiated Antibody Discovery Play

Absci Initiates IND-Enabling Studies for Abs-101, A Potential Best-In-Class Anti-Tl1a Antibody De Novo Designed and Optimized Using Generative Ai

Absci Corporation to Present Preclinical Data for ABS-101, A Potential Best-In-Class Anti-TL1A Antibody Development Program, at 42nd Annual J.P. Morgan Healthcare Conference

Absci Corporation Appoints Menelas Pangalos as Class II Director and Member of Compensation Committee of the Board, Effective January 1, 2024

Price target decreased by 14% to US$5.76

Consensus revenue estimates decrease by 42%

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Price target decreased by 15% to US$5.50

Consensus EPS estimates fall by 21%, revenue upgraded

Absci Corporation Announces Resignation of Sarah Korman as Chief Legal Officer and Interim Chief Business Officer, Effective as of September 15, 2023

Absci Corporation Appoints Zach Jonasson as Chief Business Officer, Effective from August 31, 2023

Absci Corporation Reports Impairment Results for the Second Quarter Ended June 30, 2023

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Absci Corporation and California Institute of Technology Join Forces, Bolstered by Major Grant, to Accelerate Affordable HIV Therapeutic Vaccine Development

New major risk - Share price stability

Absci Corporation Appoints Frans Van Houten to Its Board of Directors

Price target decreased by 10% to US$7.73

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Casdin Capital Engages in Discussions with Absci Corporation

Price target decreased by 28% to US$8.60

Consensus revenue estimates decrease by 23%, EPS upgraded

Full year 2022 earnings: EPS in line with expectations, revenues disappoint

Casdin Capital Engages in Discussions with Absci Corporation

Absci Deepens Scientific Advisory Board to Accelerate Generative AI Drug Creation

Absci Corporation Announces Ability to Create and Validate de novo Antibodies in Silico with Use of Zero-Shot Generative AI

Consensus forecasts updated

Price target decreased to US$12.10

High number of new and inexperienced directors

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Absci Corporation Appoints Dan Rabinovitsj as Newest Member of its Board of Directors

Chief Financial Officer exercised options to buy US$155k worth of stock.

Absci Corporation Appoints Veteran Pharma Executive Andreas Busch, PhD as Chief Innovation Officer

Absci Corporation Announces End of Nikhil Goel as Chief Strategy Officer

Price target decreased to US$13.10

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Absci GAAP EPS of -$0.32 misses by $0.01, revenue of $1M misses by $0.68M

Eli Casdin Resigns from Board of Directors of Absci Corporation

Absci teams up to help develop antibody drugs for cancer

Absci Corporation(NasdaqGS:ABSI) dropped from Russell 2000 Growth Index

First quarter 2022 earnings: EPS and revenues miss analyst expectations

High number of new and inexperienced directors

Consensus EPS estimates fall by 29%

Consensus revenue estimates fall by 17%

Merck And Absci: AI-Driven Drug Development Deal Has Promise, But May Take Years To Pay Out

High number of new and inexperienced directors

Third quarter 2021 earnings released: US$0.33 loss per share

Absci, CORP has completed an IPO in the amount of $200 million.

IPO Day With Absci CEO Sean McClain - The Google Of Synthetic Biology (Video)

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies